H Holdaas

Summary

Affiliation: Rikshospitalet University Hospital
Country: Norway

Publications

  1. doi request reprint A drug safety evaluation of everolimus in kidney transplantation
    Hallvard Holdaas
    Oslo University Hospital, Department of Transplant Medicine, Section of Nephrology, Rikshospitalet, Postbox 4950 Nydalen, N 0424 Oslo, Norway
    Expert Opin Drug Saf 11:1013-22. 2012
  2. pmc Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study
    Sara Bremer
    Department of Medical Biochemistry, Rikshospitalet University Hospital, Oslo, Norway
    J Transl Med 7:64. 2009
  3. ncbi request reprint The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials
    Hallvard Holdaas
    Medical Department, National Hospital, University of Oslo, 0027 Oslo, Norway
    Int J Cardiol 117:64-74. 2007
  4. ncbi request reprint Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy?
    Hallvard Holdaas
    Medical Department, National Hospital, University of Oslo, Oslo, Norway
    Am J Cardiovasc Drugs 5:255-69. 2005
  5. doi request reprint Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study
    Hallvard Holdaas
    Medical Department, Rikshospitalet, University of Oslo, Oslo, Norway
    Transplantation 92:410-8. 2011
  6. pmc Rosuvastatin in diabetic hemodialysis patients
    Hallvard Holdaas
    Department of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Sognsvannsveien 22, 0072 Oslo, Norway
    J Am Soc Nephrol 22:1335-41. 2011
  7. ncbi request reprint Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
    Hallvard Holdaas
    Lancet 361:2024-31. 2003
  8. ncbi request reprint Acute renal allograft rejections, a role for statins?
    H Holdaas
    Department of Medicine, National Hospital, Oslo, Norway
    Minerva Urol Nefrol 55:111-9. 2003
  9. ncbi request reprint Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study
    H Holdaas
    Rikshospitalet, Oslo, Norway
    Am J Transplant 5:2929-36. 2005
  10. ncbi request reprint Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation
    Hallvard Holdaas
    Rikshospitalet, Sognsvannsvn 20, Oslo 0072, Norway
    Nephrol Dial Transplant 20:974-80. 2005

Detail Information

Publications57

  1. doi request reprint A drug safety evaluation of everolimus in kidney transplantation
    Hallvard Holdaas
    Oslo University Hospital, Department of Transplant Medicine, Section of Nephrology, Rikshospitalet, Postbox 4950 Nydalen, N 0424 Oslo, Norway
    Expert Opin Drug Saf 11:1013-22. 2012
    ....
  2. pmc Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study
    Sara Bremer
    Department of Medical Biochemistry, Rikshospitalet University Hospital, Oslo, Norway
    J Transl Med 7:64. 2009
    ..The objective of this pilot study was to investigate the MPA PK and PD relation in combination with belatacept (2nd generation CTLA4-Ig) or cyclosporine (CsA)...
  3. ncbi request reprint The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials
    Hallvard Holdaas
    Medical Department, National Hospital, University of Oslo, 0027 Oslo, Norway
    Int J Cardiol 117:64-74. 2007
    ..Individuals with chronic kidney disease are at high risk for cardiovascular disease and have a high prevalence of hyperlipidemia. Lipid-lowering therapy may help patients with renal disease reduce their risk for cardiovascular events...
  4. ncbi request reprint Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy?
    Hallvard Holdaas
    Medical Department, National Hospital, University of Oslo, Oslo, Norway
    Am J Cardiovasc Drugs 5:255-69. 2005
    ..CVD in patients with CKD has been a neglected area of research...
  5. doi request reprint Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study
    Hallvard Holdaas
    Medical Department, Rikshospitalet, University of Oslo, Oslo, Norway
    Transplantation 92:410-8. 2011
    ..Benefits of conversion from calcineurin inhibitor (CNI) to mammalian target of rapamycin inhibitor-based immunosuppression in long-term kidney transplant patients remain uncertain...
  6. pmc Rosuvastatin in diabetic hemodialysis patients
    Hallvard Holdaas
    Department of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Sognsvannsveien 22, 0072 Oslo, Norway
    J Am Soc Nephrol 22:1335-41. 2011
    ..68; 95% CI 0.51 to 0.90). In conclusion, among hemodialysis patients with diabetes mellitus, rosuvastatin might reduce the risk of fatal and nonfatal cardiac events...
  7. ncbi request reprint Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
    Hallvard Holdaas
    Lancet 361:2024-31. 2003
    ..We investigated the effects of fluvastatin on cardiac and renal endpoints in this population...
  8. ncbi request reprint Acute renal allograft rejections, a role for statins?
    H Holdaas
    Department of Medicine, National Hospital, Oslo, Norway
    Minerva Urol Nefrol 55:111-9. 2003
    ..Although in vitro studies have provided a theoretical basis for the use of statins as immunosuppressive agents, more recent clinical placebo controlled studies have failed to confirm the initial optimism of this effect of statins...
  9. ncbi request reprint Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study
    H Holdaas
    Rikshospitalet, Oslo, Norway
    Am J Transplant 5:2929-36. 2005
    ..The lipid-lowering and cardiovascular benefits of fluvastatin are comparable to those of statins in other patient groups, and support use of fluvastatin in RTR...
  10. ncbi request reprint Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation
    Hallvard Holdaas
    Rikshospitalet, Sognsvannsvn 20, Oslo 0072, Norway
    Nephrol Dial Transplant 20:974-80. 2005
    ..The aim of the current analysis was to investigate the importance of time of initiation of therapy after transplantation, on the benefits of statin therapy...
  11. ncbi request reprint Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients
    H Holdaas
    Department of Medicine, National Hospital, Sognsvannsveien 20, 0027 Oslo, Norway
    Int J Clin Pharmacol Ther 44:163-71. 2006
    ..To assess the pharmacokinetic interaction between cyclosporine and extended-release fluvastatin (fluvastatin XL), 80 mg for 7 days, in stable renal transplant recipients...
  12. doi request reprint Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study
    H Holdaas
    Section of Nephrology, Medical Department, The National Hospital, Oslo, Norway
    Clin Transplant 22:366-71. 2008
    ....
  13. ncbi request reprint Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data
    H Holdaas
    Department of Medicine, National Hospital, N 0027 Oslo, Norway
    J Cardiovasc Risk 8:63-71. 2001
    ....
  14. ncbi request reprint Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study
    K Midtvedt
    Department of Nephrology, National Hospital, University of Oslo, Norway
    Transplantation 72:107-11. 2001
    ..The regression of left ventricular mass index is observed to a similar extent in patients treated with lisinopril or nifedipine...
  15. doi request reprint Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial
    I Holme
    Oslo University Hospital, Ulleval, Centre of Preventive Medicine, Oslo, Norway
    J Intern Med 267:567-75. 2010
    ..73 m(-2)) and analysed relationships between lipoprotein components (LC) and major coronary events (MCE) and other cardiovascular (CV) events...
  16. doi request reprint Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease
    J P Lindahl
    Department of Transplant Medicine, Section of Nephrology, Oslo University Hospital, Rikshospitalet, Sognsvannsveien 20, 0372 Oslo, Norway
    Diabetologia 56:1364-71. 2013
    ..We aimed to determine whether simultaneous pancreas and kidney (SPK) transplantation would improve patient and kidney graft survival in diabetic end-stage renal disease (ESRD) compared with kidney transplantation alone (KTA)...
  17. ncbi request reprint Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients
    A Asberg
    Medical Department, The National Hospital, Oslo, Norway
    Am J Transplant 1:382-6. 2001
    ..0% (p < 0.0001), respectively. Bilateral pharmacokinetic interaction between atorvastatin and CsA resulted in sixfold higher plasma HMG-CoA reductase inhibitory activity, but only a moderate decrease in systemic exposure of CsA...
  18. ncbi request reprint Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a double-blind randomised comparative trial
    K Midtvedt
    Medical Department, National Hospital, Rikshospitalet, 0027 Oslo, Norway
    Clin Transplant 15:426-31. 2001
    ..As monotherapy, both drugs show a "response rate" of 20-38%, depending on time interval after transplantation...
  19. ncbi request reprint Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial
    H Holdaas
    Medical Department, National Hospital, 0027 Oslo, Norway
    Kidney Int 60:1990-7. 2001
    ..The present study is the first randomized, double-blind and adequately powered study to examine the effect of statins on acute rejection of renal allografts...
  20. doi request reprint Prognostic model for total mortality in patients with haemodialysis from the Assessments of Survival and Cardiovascular Events (AURORA) study
    I Holme
    Oslo University Hospital, Ulleval, Oslo, Norway
    J Intern Med 271:463-71. 2012
    ..We used the database of the Assessment of Survival and Cardiovascular Events study to develop a prognostic model of mortality over 3-4 years...
  21. ncbi request reprint Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril
    K Midtvedt
    Department of Nephrology, The National Hospital, University of Oslo, Norway
    Transplantation 72:1787-92. 2001
    ..Patients receiving nifedipine but not lisinopril improved kidney transplant function over a period of 2 years...
  22. ncbi request reprint Atorvastatin improves endothelial function in renal-transplant recipients
    A Asberg
    Laboratory for Renal Physiology, Section of Nephrology, Medical Department, The National Hospital, N-0027 Oslo, Norway
    Nephrol Dial Transplant 16:1920-4. 2001
    ..Plasma NO levels were increased during atorvastatin treatment, indicating a possible endothelial protective effect through an "endothelial-NO pathway"...
  23. ncbi request reprint Contrasting short-term effects of nifedipine on glomerular and tubular functions in glomerulonephritic patients
    A Hartmann
    Medical Department B, National Hospital, Oslo, Norway
    J Am Soc Nephrol 5:1385-90. 1994
    ..05), respectively. It was concluded that nifedipine treatment acutely represses proximal tubular function but is without significant effect on glomerular sieving and albuminuria in these patients...
  24. ncbi request reprint The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events
    J Hjelmesaeth
    Department of Medicine, Rikshospitalet University Hospital, Oslo, Norway
    Kidney Int 69:588-95. 2006
    ..20, 95% CI=0.58-2.49, P=0.621), were independent predictors of death in the multiple Cox regression model. Early-diagnosed PTDM is a predictor of MCEs, but not of all-cause mortality, the first 8 years after renal transplantation...
  25. ncbi request reprint Ethics and safety of living kidney donation
    A Jakobsen
    Department of Surgery, Rikshospitalet, 0027 Oslo, Norway
    Transplant Proc 35:1177-8. 2003
  26. doi request reprint Quality of life in kidney donors
    G Mjøen
    Medical Department, Oslo University Hospital Rikshospitalet, Oslo, Norway
    Am J Transplant 11:1315-9. 2011
    ..They are fully reimbursed and offered life-long follow-up. All inhabitants are provided universal healthcare. This should be considered when extrapolating these results to other countries...
  27. ncbi request reprint Report from the Norwegian National Hospitals Living Donor Registry: one-year data, January 1, 2002
    L Westlie
    Norwegian National Hospital, University of Oslo, Oslo, Norway
    Transplant Proc 35:777-8. 2003
  28. ncbi request reprint Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients
    Pål Falck
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, PO Box 1068 Blindern, 0316 Oslo, Norway
    Nephrol Dial Transplant 23:1048-53. 2008
    ..The calcimimetic drug cinacalcet offers a novel therapeutic option to treat post-transplant hypercalcemia and hyperparathyroidism; however, the interaction with calcineurin inhibitors and mycophenolate has not been evaluated...
  29. pmc Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study
    Bengt Fellstrom
    Department of Medical Science, Renal Unit, University Hospital, Uppsala, Sweden
    Kidney Blood Press Res 30:314-22. 2007
    ..Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD)...
  30. doi request reprint The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study
    Vincent L M Esnault
    Pasteur Hospital, Universite de Nice Sofia Antipolis, Nice, France
    Clin Ther 30:482-98. 2008
    ....
  31. ncbi request reprint The renal safety profile of fluvastatin: results of a pooled analysis
    Hallvard Holdaas
    The Medical Department, National Hospital, University of Oslo, Oslo, Norway
    Ren Fail 28:487-92. 2006
    ..This pooled analysis demonstrates that fluvastatin treatment across the approved daily dose range of 20 mg to 80 mg does not adversely affect creatinine or creatinine clearance over time in dyslipidemic patients...
  32. ncbi request reprint No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study
    Bengt Fellstrom
    Department of Medical Science, Renal Unit, University Hospital, Uppsala, Sweden
    Clin Transplant 20:732-9. 2006
    ..This study investigated the effect of fluvastatin treatment on renal function in renal transplant recipients enrolled in the Assessment of Lescol in Renal Transplantation (ALERT) trial...
  33. ncbi request reprint Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients
    Jonathan B Singer
    Clinical Pharmacogenetics, Novartis Institutes for BioMedical Research, Cambridge, MA, USA
    J Lipid Res 48:2072-8. 2007
    ..Polymorphisms in 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) previously reported to affect the efficacy of pravastatin did not show a similar effect on the reduction of LDL cholesterol by fluvastatin...
  34. doi request reprint Long-term clinical outcome of paediatric kidneys transplanted to adults
    Aksel Foss
    Department of Surgery, Section of Transplant Surgery, Rikshospitalet University Hospital, N 0027 Oslo, Norway
    Nephrol Dial Transplant 23:726-9. 2008
    ..We have earlier shown an increase in the size and excellent graft function of paediatric kidneys transplanted to adults up to 1 year following transplantation. This study was performed to assess the long-term outcome of these transplants...
  35. ncbi request reprint Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients
    Anders Asberg
    Laboratory for Renal Physiology, Medical Department, Rikshospitalet, Oslo, Norway
    Transplantation 82:62-8. 2006
    ..Calcineurin inhibitor (CNI)-free regimens posttransplantation have been claimed to conserve graft function in addition to reduce the risk factors for cardiovascular and malignant disease in renal transplant recipients...
  36. ncbi request reprint The use of statins after solid organ transplantation
    Hallvard Holdaas
    Nephrol Dial Transplant 17:1537. 2002
  37. ncbi request reprint fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study
    Alan G Jardine
    Western Infirmary, Glasgow, Scotland, UK
    Am J Transplant 4:988-95. 2004
    ..The subgroups included patients at lower cardiovascular risk, who were younger, nondiabetic, nonsmokers and without pre-existing CVD. These data support the early introduction of statins following renal transplantation...
  38. ncbi request reprint Fluvastatin and fluvastatin extended release: a clinical and safety profile
    Anders Asberg
    Medical Department, National Hospital, Oslo, Norway
    Expert Rev Cardiovasc Ther 2:641-52. 2004
    ..The demonstration of the safe use of fluvastatin in a wide range of patients may be associated with the predominant acid form of the drug in vivo, as well as its predominant metabolism via the cytochrome P450 2C9 pathway...
  39. ncbi request reprint Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial
    Bengt Fellstrom
    Department of Medical Science, Renal Science, Renal Unit, University Hospital, Uppsala, Sweden
    Transplantation 79:205-12. 2005
    ....
  40. ncbi request reprint Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients
    Monica Hermann
    Department of Pharmacology, School of Pharmacy, University of Oslo, PB 1068, Blindern, N 0316 Oslo, Norway
    Eur J Clin Pharmacol 61:59-62. 2005
    ..The aim of the present study was to evaluate the possible influence of atorvastatin on the pharmacokinetics of cyclosporine (INN ciclosporin) and its main metabolites, AM1 and AM9, in renal transplant recipients...
  41. ncbi request reprint Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial
    Bengt Fellstrom
    University Hospital, Uppsala, Sweden
    Transplantation 79:1160-3. 2005
    ..We evaluated the effects of baseline renal-transplant function on mortality and cardiovascular and renal endpoints in 1,052 placebo-treated patients of the Assessment of Lescol in Renal Transplantation trial...
  42. ncbi request reprint Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: lessons to be learnt from the assessment of Lescol in renal transplantation (ALERT) trial
    Hallvard Holdaas
    Am J Transplant 5:1574-5. 2005
  43. ncbi request reprint Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation
    Alberto Corsini
    Department of Pharmacological Sciences, University of Milan, Milan, Italy
    Ren Fail 27:259-73. 2005
    ..This article characterizes the dyslipidemia observed in these clinical settings and reviews the clinical experience with fluvastatin...
  44. ncbi request reprint [Staging and measurement of renal function in chronic renal conditions]
    Anders Hartmann
    Nyreseksjonen, Medisinsk avdeling, Rikshospitalet
    Tidsskr Nor Laegeforen 126:1198-200. 2006
    ..We address the importance and implications of these new definitions...
  45. ncbi request reprint Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality
    Inga Soveri
    Department of Medical Sciences, Uppsala University Hospital, entr 40, 75185, Uppsala, Sweden
    Nephrol Dial Transplant 21:2282-9. 2006
    ..The impact of renal dysfunction was compared with traditional risk factors for cardiovascular morbidity and mortality in 1052 placebo-treated patients of the ALERT trial...
  46. ncbi request reprint Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study
    Alan G Jardine
    University of Glasgow, UK
    Am J Kidney Dis 46:529-36. 2005
    ..We analyzed the data in the placebo arm of Assessment of Lescol in Renal Transplantation (ALERT) to improve our understanding of the relationship between cardiovascular risk factors and outcomes in this unique population...
  47. ncbi request reprint Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial
    Bengt Fellstrom
    University Hospital, Uppsala, Sweden
    Kidney Int 66:1549-55. 2004
    ..The aim of the present study was to evaluate the effect of fluvastatin on long-term renal transplant function and development of chronic allograft nephropathy in the ALERT (Assessment of Lescol in Renal Transplantation) study...
  48. ncbi request reprint Risk for myopathy with statin therapy in high-risk patients
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Baylor College of Medicine, 6565 Fannin, Mail Station A601, Suite A656, Houston, TX 77030, USA
    Arch Intern Med 163:553-64. 2003
    ..Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease...
  49. ncbi request reprint Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation
    Anders Asberg
    Laboratory for Renal Physiology, Section of Nephrology, Medical Department, The National Hospital, Oslo, Norway
    Clin Transplant 17:385-90. 2003
    ..We therefore performed this study to assess the effect of fluvastatin on endothelial function in renal transplant recipients...
  50. ncbi request reprint [How are living kidney donors doing?]
    Lars Westlie
    Immunologisk institutt, Rikshospitalet 0027 Oslo
    Tidsskr Nor Laegeforen 123:1060-2. 2003
  51. ncbi request reprint The risk of living kidney donation
    Anders Hartmann
    Nephrol Dial Transplant 18:871-3. 2003
  52. ncbi request reprint [Is current practice concerning living donors in kidney transplantations acceptable?]
    Lars Westlie
    Immunologisk institutt, Rikshospitalet 0027 Oslo
    Tidsskr Nor Laegeforen 123:1063-5. 2003
  53. ncbi request reprint [Type 2 diabetes and nephropathy--new studies, new treatment strategies?]
    Ingrid Os
    Nyremedisinsk avdeling Ullevål universitetssykehus 0407 Oslo
    Tidsskr Nor Laegeforen 122:918-20. 2002
    ..It is important to lower the blood pressure to inhibit progression of renal failure and to prevent micro- and macrovascular disease in these patients. There is an ongoing discussion on what should be the drug of choice...
  54. ncbi request reprint Statin therapy for prevention of coronary artery disease. The earlier the better or the longer the better?
    Hallvard Holdaas
    Eur Heart J 29:425-6. 2008
  55. ncbi request reprint Clinicians underestimate gastrointestinal symptoms and overestimate quality of life in renal transplant recipients: a multinational survey of nephrologists
    Henrik Ekberg
    Department of Nephrology and Transplantation, Malmo University Hospital, Lund University, Malmo, Sweden
    Transplantation 84:1052-4. 2007
    ..Improving patient-clinician communication could lead to more informed management, resulting in better HRQoL and increased graft survival...
  56. ncbi request reprint Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients
    Henrik Ekberg
    Department of Nephrology and Transplantation, Malmo University Hospital, Lund University, Malmo, Sweden
    Transplantation 83:282-9. 2007
    ..Immunosuppressive therapies have been associated with gastrointestinal (GI) side effects, which may impair health-related quality of life (HRQoL)...
  57. ncbi request reprint Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study
    Cecilia Montgomery Oien
    Faculty of Medicine, University of Oslo, Norway
    Clin Transplant 20:374-82. 2006
    ..Whether renal transplantation restores the gender-dependent cardiac protection and whether there is a difference in the impact of risk factors is not known...